Rob Collin (CSO) is a scientist with molecular knowledge and expertise in discovering and developing RNA therapy for specific genetic subtypes of retinal disease. Carel Hoyng (COO) is an ophthalmologist with over three decades of expertise on the clinical aspects of inherited retinal diseases, and experience in conducting and organizing clinical trials.
Chief Scientific Officer, Founder, Key opinion leader Retinak Disease
“My ultimate goal is to find a cure for inherited retinal diseases”
Chief Scientific Officer, Founder, Inventor RNA Therapy
“Due to their high specificity, antisense oligonucleotides hold great promise to correct RNA defects underlying many inherited diseases”